FDA: Benicar Linked to Celiac Disease, Enteropathy

December 13, 2013 Last Updated on 04/29/2015

Comments |

At A Glance

This Alert Affects:
Patients who took Benicar (generic: olmesartan medoxomil) and developed gastrointestinal problems.
Side Effects:
Sprue-like enteropathy, celiac disease, villous atrophy, chronic diarrhea, substantial weight loss, and hospitalization.
Manufacturer:
Daiichi Sankyo Inc.
What is Benicar?
Benicar is used to treat high blood pressure and belongs to a group of drugs known as angiotensin II receptor blockers (ARBs).
FDA Warning:
In July 2013, the FDA issued a safety communication announcing a link between Benicar and sprue-like enteropathy, a condition that mimics celiac disease. The agency announced it would be updating the drug's labeling to reflect this risk.
Type of Lawsuit:
Mass Tort